A buyer flags a component. Your supplier's declaration looks stale. Engineering says the part can't change without requalification. Procurement says there's no second source. Then someone notices the substance in that component is on REACH Annex XIV.
That's the moment Annex XIV stops being a legal topic and becomes an operations problem.
Most new EHS managers meet REACH through SDS updates, supplier questionnaires, and Candidate List screening. That's manageable. Annex XIV is different. It's the part of REACH where a substance reaches the end of its normal commercial life unless a company secures authorization for a specific use. If you're responsible for continuity of supply, product compliance, and audit readiness, you can't treat it as a list to check once a year.
The risk isn't only that a substance is listed. A greater risk is that your business discovers it too late. By then, the conversation gets ugly fast. Can production continue. Is the use exempt. Who owns the application. Is there an alternative. Which customers need to be told. What happens to stock already committed to builds.
That's why I advise companies to treat REACH Annex XIV as a BOM-level risk management issue, not a narrow chemicals issue. If the affected substance sits inside coatings, adhesives, plastics, masterbatches, imported assemblies, or legacy specifications, your exposure can hide in plain sight. A clean top-level declaration won't save you if the underlying component data is weak.
Introduction The End of the Line for a Substance
A new EHS manager usually inherits a filing system, a supplier list, and a false sense of comfort.
On paper, everything looks under control. The company has substance declarations. The ERP has part numbers. The quality team keeps approved vendor lists. Then a customer asks whether a critical assembly contains a substance subject to authorization, and the answer isn't immediately available. Someone digs through old specifications, outdated SDS files, and supplier emails. That's when the gap shows up. The substance wasn't just on a watchlist. It had moved to the point where continued use depends on authorization or a hard stop.
That's what REACH Annex XIV represents. It's the line a substance crosses when regulators decide its risks are serious enough that ordinary market access is no longer acceptable.
Practical rule: If your team first discusses Annex XIV after a customer question or a supplier alert, you're already behind.
The business impact shows up in familiar places:
- Engineering disruption: redesign work lands on teams that were already fully loaded.
- Procurement pressure: buyers scramble for alternate sources without equivalent documentation.
- Commercial exposure: account managers can't answer customer compliance questions confidently.
- Legal risk: internal teams discover that assumptions about continued use were never documented.
New EHS managers often think the problem is chemical complexity. It usually isn't. The problem is timing and ownership. No one built a process that links regulatory change to live BOMs, approved materials, and supplier evidence.
You don't fix that with a one-off spreadsheet review. You fix it by treating Annex XIV as a trigger for structured decisions. Continue with authorization if there's a defensible path. Substitute if the substance isn't strategically worth keeping. Stop use if neither route is realistic.
What Is REACH Annex XIV The Authorisation List
REACH Annex XIV is the Authorisation List. It is the point where an SVHC stops being a monitoring issue and becomes a use-by-use business decision. If your company wants to keep using a listed substance after the sunset date, you need authorization for that specific use, unless an exemption applies. If not, use must stop.
What makes Annex XIV different
Many teams miss a core fact. Annex XIV is not just a list of hazardous substances. It is a legal control mechanism under REACH that forces companies to justify continued use or replace the substance. As described in the Annex XIV overview, the list currently includes 42 distinct substances subject to authorization, and the inclusion criteria are tied to Article 57 categories such as CMR, PBT, vPvB, and substances of equivalent concern, including endocrine disruptors.
The legal structure is important because Annex XIV is not an informal warning. It is designed to remove routine market access. A listed substance can remain in your business only through an active, documented path.
Examples make that real. MDA and 4-(1,1,3,3-Tetramethylbutyl)phenol, ethoxylated, both moved from listing to sunset on fixed regulatory timelines. For manufacturers, that is the practical lesson. The clock runs against existing specifications, approved suppliers, and customer commitments.
Don't confuse it with the Candidate List or Annex XVII
These three lists trigger different decisions, and mixing them up leads to bad timing.
| List | What it means in practice | What your team should do |
|---|---|---|
| Candidate List | A substance has been identified as an SVHC and may move toward stronger controls | Screen BOMs, supplier declarations, and design approvals early |
| Annex XIV | Continued use or placement on the market may require authorization for each relevant use | Decide whether to substitute, seek authorization, or phase out |
| Annex XVII | Specific restrictions apply to manufacture, placing on the market, or use | Check the restriction text, thresholds, exemptions, and affected applications |
The distinction is simple. Candidate List inclusion is an escalation signal. Annex XIV is a deadline tied to business continuity.
Once a substance is on Annex XIV, passive monitoring is not enough. You need a position for every affected use in every affected product line.
Why EHS managers should care immediately
Annex XIV risk rarely sits neatly at finished-product level. It often sits lower in the stack, inside a curing agent, additive package, surface treatment, polymer formulation, or process chemical. That is why high-level supplier statements fail so often during customer reviews and internal audits.
Handle Annex XIV at BOM level. Map the listed substance to part numbers, formulations, manufacturing uses, supplier sites, and customer-approved configurations. Then rank each exposure by sunset date, substitution difficulty, revenue impact, and evidence quality.
That is how you turn Annex XIV from a late-stage compliance problem into a supply chain decision framework. Without that level of control, your team will find the issue only after a supplier change, customer request, or renewal audit forces the question.
The Journey of a Substance to Annex XIV
Your supplier confirms a material is still available. Then a customer asks whether any use in that material depends on a substance heading toward authorisation. If your team has only checked finished products, you are already late.
A substance reaches Annex XIV through a visible regulatory sequence. Teams that track that sequence at BOM level get decision time. Teams that wait for formal listing end up choosing under pressure, with fewer technical and commercial options left.
The pipeline you need to watch
The process usually starts with the Candidate List. According to QPoint Tech's explanation of REACH lists, the Candidate List has undergone 25 updates since its inception, with changes occurring every 6 months. That cadence gives you repeated chances to catch exposure before Annex XIV turns the issue into a hard business deadline.
Once a substance is identified as an SVHC and placed on the Candidate List, it enters the pool of substances that can be prioritised for Annex XIV. The legal criteria sit in Article 57 on substances to be included in Annex XIV. Read that article if you want to understand why one substance moves forward while another stalls.
The practical lesson is simple. Candidate List entry is not background news. It is an early supply chain signal.
A practical sequence for industry teams
Use this five-stage model.
SVHC identification
Regulators identify the substance based on hazard properties.Candidate List entry
Start tracing the substance through purchased materials, mixtures, process uses, and articles. Do not stop at supplier declarations for top-level assemblies.Prioritisation discussions
ECHA and stakeholders assess which Candidate List substances should move toward Annex XIV. This is the point where strong companies build exposure maps and weak companies keep waiting.Recommendation for Annex XIV
Now you need line-of-sight to the exact parts, formulations, plants, and supplier sites involved.Formal inclusion with dates
Once the listing includes application and sunset dates, every affected use needs a business decision tied to revenue, qualification effort, and replacement feasibility.
What smart companies do before formal listing
Use the warning period to build an internal impact map that procurement, EHS, regulatory, and engineering can all use.
- Map the substance to BOMs: trace it to finished goods, subassemblies, formulations, and production uses.
- Rank exposure by business risk: focus first on sole-source materials, customer-locked specifications, and high-revenue platforms.
- Test supplier evidence: ask for use-specific confirmations, concentration details where relevant, and site-level clarity. Generic compliance letters are weak evidence.
- Push alternatives early: involve R&D, quality, and product stewardship before commercial teams promise continuity.
- Set decision triggers: define when a substance moves from watchlist to substitution project, exemption review, or authorisation assessment.
The substance journey provides a valuable warning. Use it to protect product lines before sunset dates start driving your decisions for you.
Navigating the Authorisation Process
If your company decides it must continue using an Annex XIV substance after the sunset date, prepare for a serious project. This isn't paperwork cleanup. It's a technical, commercial, and regulatory defense of continued use.
What the process actually demands
According to Regilient's overview of REACH Annex XIV authorization, REACH Annex XIV creates a strict cause-effect chain in which substances classified as Carcinogenic, Mutagenic, or Reprotoxic trigger a sunset date prohibition, and downstream users must secure explicit authorization from ECHA or stop use entirely. The same source states that the application requires a Chemical Safety Report, a Socio-economic Analysis, and an Analysis of Alternatives, with evaluation by the Risk Assessment Committee (RAC) and the Socio-economic Analysis Committee (SEAC) before the Latest Application Date (LAD).
For the legal framework behind the procedure, keep Title VII on authorisation close at hand.
The three pillars that decide whether your application stands up
Not all parts of the dossier carry the same practical burden. These three do.
Chemical Safety Report
The CSR is where you demonstrate that you understand the risks tied to the specific use and the conditions under which the substance is handled. If the use description is vague or the operating conditions are inconsistent across sites, your application weakens immediately.
Multi-site manufacturers run into trouble. Plant A may have one control setup, Plant B another, and contract manufacturing may add a third variation. If your actual use conditions aren't harmonized, don't expect the dossier to magically fix the inconsistency.
Analysis of Alternatives
At this juncture, many applications become uncomfortable. The AoA doesn't ask whether alternatives are perfect. It asks whether safer substitutes are technically feasible.
That forces hard internal conversations:
- R&D must test realistic substitutes, not theoretical options.
- Quality must define qualification criteria for replacement materials.
- Procurement must verify supply continuity for candidate alternatives.
- Commercial teams must assess customer approval impacts if specifications change.
A weak alternatives analysis tells regulators that the company started too late or never took substitution seriously.
Socio-economic Analysis
The SEA exists to justify continued use in spite of the risk. It isn't a generic statement that the substance is important to the business. It must connect the use to economic and operational consequences in a way that is specific and defensible.
Authorization is a last resort. If your internal position is “we'll just apply,” you probably haven't done the hard work on substitution or scope control.
How to manage the timeline without losing control
The LAD matters because it determines whether the business can keep using the substance while the application is evaluated. Miss it, and your options narrow fast.
I recommend a simple internal gate model:
| Internal gate | Decision owner | What must be true |
|---|---|---|
| Gate 1 Screening | EHS and regulatory | Substance, use, and legal status confirmed |
| Gate 2 Feasibility | R&D, operations, procurement | Alternatives screened and business dependency mapped |
| Gate 3 Strategy | Leadership | Decide authorization, substitution, or exit |
| Gate 4 Dossier readiness | Regulatory lead | CSR, AoA, SEA, and supporting evidence aligned |
If your company can't pass Gate 2 cleanly, don't pretend Gate 4 will save you. Most Annex XIV failures start as internal indecision.
Your Obligations and Practical Compliance Steps
A sunset date gets real when production asks for a release, procurement says the supplier declaration is "in progress," and no one can prove whether the use is covered. That is how Annex XIV failures start. Not with chemistry. With missing ownership, weak records, and BOM data that never made it into a decision file.
Your job is to turn Annex XIV from a legal question into an operating control. Start at BOM level, then push accountability into each function that can create or remove risk.
What each function needs to own
Manufacturers and importers need a verified view of where Annex XIV substances appear across substances, mixtures, components, and finished goods tied to EU supply. Distributors need disciplined product status control and clean customer communication. Downstream users need a documented answer to a simple question: is this exact use authorized, exempt, or heading toward stop use?
Ownership usually fails because the data sits in separate systems. ERP holds part numbers. PLM holds formulations. Procurement has supplier statements in email. EHS has the regulatory assessment. If those records do not connect, your company will make decisions on partial facts.
Use this checklist to fix that:
- Build a live substance register: connect Annex XIV exposure to part numbers, materials, suppliers, sites, and affected customers.
- Rewrite supplier questionnaires: ask for substance identity, use coverage, authorization status, exemption basis, and relevant dates. Generic "REACH compliant" language is useless.
- Control evidence by version and date: expired SDSs, old declarations, and undated confirmations should not support a release decision.
- Document legal positions: if a team concludes a use is exempt or out of scope, record the legal basis, product scope, and supporting evidence.
- Escalate changes through change control: any reformulation, supplier switch, or specification update that affects Annex XIV status must trigger review by regulatory, procurement, and engineering.
The imported articles problem
Imported articles are where many companies lose control. According to the legal appraisal discussing REACH authorization and imported articles, Annex XIV creates a difficult legal question for SVHCs embedded in imported articles, and Article 56(1) REACH explicitly bans domestic use without authorization the legal appraisal discussing REACH authorization and imported articles.
Treat that ambiguity as a risk signal, not a loophole.
If you import finished assemblies, coated parts, cables, electronics, or treated articles, test your exposure at BOM level. Identify which components may contain an Annex XIV substance, which EU sites handle or use them, and whether any downstream step could amount to use that needs authorization. For broader context on substances that can move toward authorization, review ReachLex's overview of the Substance of Very High Concern list.
Silence from a non-EU supplier is not evidence. It is an unresolved risk.
What audit-ready looks like
Audit-ready files are concise, traceable, and tied to business decisions. A regulator, customer, or internal auditor should be able to see the substance, the use, the legal position, and the approval trail without chasing emails across three departments.
A solid file should show:
| Evidence area | What good looks like |
|---|---|
| Substance identification | CAS, EC, substance name, supplier mapping, and affected BOM references |
| Use analysis | Where the substance appears in products, processes, sites, and customer programs |
| Regulatory decision | Authorization, substitution, exemption, phase-out, or stop-supply decision with rationale |
| Supplier communication | Dated declarations, follow-ups, gaps, and escalation records |
| Internal approvals | Sign-off from regulatory, procurement, engineering, operations, and legal where needed |
If your team cannot explain its Annex XIV position in one meeting, with records that match the BOM and current supply base, the control system is not ready.
Strategic Risk Mitigation for Your Supply Chain
A substance hits Annex XIV. One plant can still buy it. Another site uses it in a customer-locked formulation. Procurement says supply is stable. Engineering says redesign will take nine months. Sales has already promised delivery through the sunset date. That is how a regulatory issue turns into a BOM-level business failure.
Reactive compliance costs more because it shows up late, when your options are narrow and expensive. Multi-sector manufacturers need an Annex XIV control model tied to parts, formulations, approved vendors, and customer specifications. If your review stops at the substance name, you are managing paperwork, not supply continuity.
Why BOM-level control matters now
ECHA's February 2026 consultation recommended four new substances for Annex XIV, including UV stabilizers, flame retardants, and photoinitiators Certivo's discussion of the February 2026 consultation.
Those substance groups rarely stay isolated in one product line. They can sit in coatings, housings, composites, inks, adhesives, and specialty mixes across multiple business units. A single listing can therefore create parallel risks. Redesign risk, supplier failure risk, customer requalification risk, and plant-specific use risk.
That is why broad compliance statements fail. “Supplier confirms REACH compliance” does not tell you which BOMs are exposed, which sites use the substance, or which customer programs will stall if the material disappears.
The framework I recommend
Build your program around decision speed at the BOM level.
Tier your exposure by business impact
Group affected materials and parts into clear risk bands. Start with confirmed Annex XIV content. Add suspected content where supplier data is weak or outdated. Then separate items tied to customer-controlled specifications, validated formulations, or regulated end uses. This gives you a real priority list instead of a long screening queue.
Connect regulatory status to sourcing constraints
A listed substance in a standard, dual-sourced raw material is a manageable sourcing project. The same substance in a single-source component approved by the customer is a continuity threat that belongs in leadership review. Treat those cases differently from the start.
Start substitution as a commercial project
Substitution fails when it sits only with the lab. Give it owners from engineering, procurement, quality, operations, and account management. Define acceptance criteria early. Performance, qualification timing, customer approval, tooling impact, cost, and regional supply availability all need a decision path.
The right question is not “Is this substance on Annex XIV?” The right question is “Which BOMs, plants, customers, and revenues break first if this use stops?”
A practical planning model for multi-sector manufacturers
Use a four-lane board for each exposed substance and review it monthly.
Lane 1 Watch
Substance under scrutiny, low current dependency, supplier confirmation incomplete, no immediate production threat.Lane 2 Contain
Known use, limited BOM spread, alternative material or redesign path looks realistic within normal change control.Lane 3 Escalate
High dependency, customer approval barriers, single-source exposure, or unclear article and use boundaries across sites.Lane 4 Decide
Leadership chooses between authorization reliance, accelerated substitution, planned phase-out, or stop-supply.
This model works because it converts regulatory movement into sourcing and product decisions. It also exposes the hidden cases that hurt manufacturers most. The substance is known to compliance, but no one has tied it to approved vendor lists, customer specs, inventory strategy, or end-of-life planning.
The companies that handle Annex XIV well do the boring work early. They screen regularly. They assign owners. They test alternatives before a deadline forces the issue. They make BOM visibility a supply chain control, not a regulatory side task.
How to Check for Annex XIV Substances with ReachLex
A buyer approves a material change. Engineering releases the part. Production keeps running. Then someone finds an Annex XIV substance buried in a supplier declaration, and the core problem starts. You are no longer checking one chemical. You are checking which BOMs, sites, customers, and revenue streams now carry authorization risk.
Teams waste time and introduce errors during manual checking. Spreadsheets, saved PDFs, and copied substance names break down fast once the same material appears across multiple products, plants, and suppliers.
The fastest way to run a check
Use a fixed search order and make your team follow it every time. Start with the identifier that gives the cleanest match.
Start with the best available identifier
Pull the CAS number, EC number, or full substance name from the SDS, specification, declaration, or supplier file.Run the search
Search using the identifier least likely to create ambiguity. CAS usually comes first. EC number is often better when supplier systems are aligned to EU records. Chemical name is the fallback, not the default.Confirm the regulatory profile
Check whether the substance appears on Annex XIV and review the listing details that affect authorization status.Translate the result into business impact
If the substance is listed, identify the affected BOMs, approved vendors, sites, and customer-facing products. Then check whether supplier declarations are current and whether any use assumptions need legal or technical review.
What to look for in the result
A search result only helps if your team reads it the right way.
Focus on these checks:
Exact match or lookalike?
Verify the substance against CAS or EC whenever possible. Near-name matches create bad decisions.Relevant to your actual use?
Annex XIV exposure depends on how the substance is used and supplied, not just on a name match in isolation.Connected to internal records?
The result should link back to material masters, BOMs, supplier files, and open change actions. If it does not, you have a lookup result, not a control.
Turn searches into a controlled workflow
The point is not faster searching alone. The point is repeatable decisions that stand up under audit and give sourcing and engineering time to act.
Set a rule that every Annex XIV screening event produces the same minimum output:
| Output | Why it matters |
|---|---|
| Search identifier used | Shows exactly what the reviewer checked |
| Matched substance result | Reduces confusion over synonyms and near matches |
| Regulatory conclusion | States whether Annex XIV is triggered |
| Affected internal records | Connects the finding to materials, BOMs, or products |
| Assigned follow-up owner | Prevents stalled actions |
That workflow matters most in multi-sector manufacturing. A single listed substance can sit in coatings, adhesives, process chemicals, spare parts, or legacy components with different approval paths by business unit. If your check stops at the substance name, you miss the full exposure. Build the review around BOM impact, supplier dependency, and deadline-driven change control.
New EHS managers often ask for more headcount first. Fix the search discipline first. Standardized screening, documented outputs, and BOM-level escalation rules usually remove more risk than another inbox full of unmanaged substance alerts.
ReachLex helps compliance teams turn Annex XIV screening into a repeatable process instead of a scramble through scattered documents. Use ReachLex to search substances by CAS, EC, or name, review consolidated EU regulatory text, and give your team one place to verify obligations before they become supply chain disruptions.